Condition

Diffuse Large B Cell Lymphoma (DLBCL) clinical trials and research

• 41Clinical trials
• 1New in 30 days
• 31Countries

Newest Diffuse Large B Cell Lymphoma (DLBCL) clinical trials

All recruiting trials (41)

• ctDNA testing in newly diagnosed DLBCL or HGBL to predict treatment outcomes

  This study checks if measuring circulating tumor DNA in blood after first-line therapy can predict whether the disease will stay away or come back in people with DLBCL or HGBL.

  Recruiting at 2 sites Peking University People's Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07878351

• Proton Therapy for Mediastinal Lymphoma in Denmark

  This study tests whether using proton therapy for mediastinal lymphoma can lower late-toxicity risk compared with photon therapy in adults.

  Recruiting Copenhagen University Hospital, Rigshospitalet · Copenhagen, Select A State · NCT07817641

• Memory-Enhanced CAR-T Therapy for Relapsed/Refractory Large B-Cell Lymphoma

  This trial tests memory-enhanced 7×19-THEMIS CAR-T cells in adults with relapsed or refractory large B-cell lymphoma to see how safe they are and whether tumors shrink or disappear.

  Recruiting Phase 1/2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07788118

• UB-VV400 with rapamycin in relapsed/refractory B-cell lymphomas

  A phase 1/2 trial tests UB-VV400 plus rapamycin in adults with relapsed or refractory B-cell lymphomas to see if it is safe and shows anti-tumor activity.

  Recruiting at 2 sites Phase 1/2 Umoja Biopharma · Irvine, California and 1 other locations · NCT07735533

• Rocbrutinib and Lacutoclax in B-cell cancers

  This study tests whether Rocbrutinib plus Lacutoclax can help adults with B-cell malignancies, including CLL/SLL, MCL, DLBCL, FL, WM, who have had prior therapy or are treatment-naïve under specific criteria.

  Recruiting Phase 1/2 Guangzhou Lupeng Pharmaceutical Company LTD. · Tianjin · NCT07609862

• Polatuzumab vedotin with Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in untreated DLBCL (MCD/BN2/N1)

  This study tests a targeted combination therapy to see if it can treat previously untreated DLBCL with specific molecular subtypes.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07608978

• Pomalidomide, anti–PD‑1 antibody, and selinexor for relapsed/refractory primary CNS diffuse large B‑cell lymphoma

  This trial tests whether combining pomalidomide, a PD‑1 blocking antibody, and selinexor can help adults with relapsed or refractory primary central nervous system diffuse large B‑cell lymphoma.

  Recruiting Phase 2 Beijing Tongren Hospital · Beijing, Beijing Municipality · NCT07523737

• NexCAR19 (Talikabtagene Autoleucel) for relapsed or refractory B‑cell leukemias and lymphomas

  This trial will test modified versions of a patient's own T cells (NexCAR19/Talikabtagene Autoleucel) to see if they can control relapsed or refractory B‑cell leukemias and lymphomas in adults.

  Recruiting at 3 sites Phase 2/3 Health Institutes of Turkey · Ankara and 3 other locations · NCT07502118

• Genetic subtype–matched first-line treatment for newly diagnosed DLBCL with TP53 mutation.

  This treatment plan will try Pola‑R‑CHP for people newly diagnosed with DLBCL and a TP53 mutation, adding orelabrutinib only for those whose tumors have the MCD/BN2 genetic subtype.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07499271

• Celecoxib Plus R-CHOP vs R-CHOP in newly diagnosed CD5-positive DLBCL

  This study tests whether adding celecoxib to standard R-CHOP therapy helps people with newly diagnosed CD5-positive DLBCL see more complete responses.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07494565

• Chidamide with reduced-dose R-mini CHOP followed by chidamide plus CD20 antibody maintenance for elderly MYC/BCL2 double-expressor DLBCL

  This trial tests whether adding chidamide to reduced-dose R-mini CHOP, followed by chidamide plus a CD20 antibody, helps people aged 70 and older with newly diagnosed MYC/BCL2 double-expressor DLBCL live longer without disease progression.

  Recruiting Phase 2 The First Hospital of Jilin University · Changchun, Jilin · NCT07493148

• Chidamide as maintenance for HBV-positive diffuse large B‑cell lymphoma after R‑CHOP

  This trial tests whether taking chidamide as maintenance helps adults with HBV-positive diffuse large B‑cell lymphoma who achieved a complete response after R‑CHOP.

  Recruiting Phase 3 The First Hospital of Jilin University · Changchun, Jilin · NCT07493109

• Radiation, Vancomycin, and CAR-T for B-Cell Lymphoma

  This trial tests if giving radiation and the antibiotic vancomycin before CAR-T cell therapy is feasible for adults with large B-cell lymphomas.

  Recruiting Phase 1 Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT07478848

• TC011 (CD19 CAR-T) for relapsed or refractory large B‑cell lymphoma

  This will test a CD19-targeted CAR-T therapy called TC011 in adults whose large B‑cell lymphoma has relapsed or not responded after prior treatments.

  Recruiting Phase 1/2 TICAROS Co., Ltd. · Seoul, Seoul · NCT07473167

• CRP regimen for older adults with untreated double‑expressor diffuse large B‑cell lymphoma

  This trial will try the CRP drug combination (chidamide, rituximab, and polatuzumab vedotin) as first-line treatment for older adults with previously untreated double-expressor DLBCL.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07397832

• Zanubrutinib plus Pola-R-CHP for newly diagnosed high-risk diffuse large B‑cell lymphoma

  This tests whether adding the BTK inhibitor zanubrutinib to a Pola-R-CHP regimen helps people with newly diagnosed DLBCL who have high-risk features.

  Recruiting Phase 2 Beijing Tongren Hospital · Beijing, Beijing Municipality · NCT07371923

• KSV01 injection for relapsed or refractory diffuse large B‑cell lymphoma

  This trial will test a new injectable treatment called KSV01 in adults with relapsed or refractory diffuse large B‑cell lymphoma to see if it is safe and can help control the cancer.

  Recruiting Phase 1 TCRx Therapeutics Co.Ltd · Wuhan, Hubei · NCT07260812

• Rocbrutinib for adults with relapsed or refractory non‑GCB diffuse large B‑cell lymphoma

  This test tries rocbritinib alone versus the doctor's choice of bendamustine‑rituximab or lenalidomide‑rituximab in adults whose non‑GCB diffuse large B‑cell lymphoma has relapsed or not responded after at least two prior treatments.

  Recruiting at 2 sites Phase 2 Guangzhou Lupeng Pharmaceutical Company LTD. · Hefei, Anhui and 40 other locations · NCT07189065

• Ronde-cel versus standard CD19 CAR T‑cell therapy for relapsed or refractory large B‑cell lymphoma

  This test sees if ronde-cel, a CAR T therapy that targets both CD19 and CD20, works better than currently used CD19 CAR T therapies for adults whose large B‑cell lymphoma returned or did not respond after first‑line treatment.

  Recruiting at 41 sites Phase 3 Lyell Immunopharma, Inc. · Gilbert, Arizona and 43 other locations · NCT07188558

• HDM2005 combined with standard treatment for diffuse large B-cell lymphoma.

  We are testing whether adding HDM2005 to standard chemotherapy helps adults with diffuse large B‑cell lymphoma who are either newly diagnosed or whose disease has returned.

  Recruiting Phase 1/2 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality and 20 other locations · NCT07124936

• Xinlikang capsules for chemo-related fatigue and immune problems after DLBCL treatment

  This trial will test whether Xinlikang capsules can reduce chemotherapy-related fatigue and improve peripheral blood lymphocyte counts in adults with diffuse large B-cell lymphoma who are in complete remission after first-line chemotherapy.

  Recruiting Phase 2/3 Sun Yat-sen University · Guangzhou, Guangdong · NCT07084662

• Orelabrutinib plus Pola‑R‑CHP for untreated non‑GCB diffuse large B‑cell lymphoma

  This trial tests whether adding orelabrutinib to the Pola‑R‑CHP chemotherapy improves responses in adults with newly diagnosed non‑GCB diffuse large B‑cell lymphoma.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07078500

• Anbalcabtagene autoleucel for relapsed or refractory CNS B‑cell lymphoma

  This trial will test whether Anbal‑cel, an anti‑CD19 CAR‑T therapy, is safe and helps adults with relapsed or refractory primary or secondary CNS diffuse large B‑cell lymphoma.

  Recruiting Phase 2 Asan Medical Center · Seoul · NCT07062627

• Testing EXS73565 for patients with relapsed or refractory B-cell cancers

  This study is testing a new oral medication called EXS73565 to see if it can help adults with B-cell cancers that haven't responded to other treatments.

  Recruiting at 17 sites Phase 1 Exscientia AI Limited · Tbilisi and 16 other locations · NCT06980116

• Mosunetuzumab consolidation for older DLBCL patients with detectable ctDNA after pola‑R‑mini‑CHP

  This trial will try mosunetuzumab in older people with DLBCL who have detectable ctDNA after finishing pola‑R‑mini‑CHP to see if it clears leftover cancer DNA and lowers the chance of relapse.

  Recruiting Phase 2 University of Rochester · Rochester, New York · NCT06828991

• Observational study of relapsed diffuse large B-cell lymphoma presenting as indolent lymphoma

  This study looks at how diffuse large B-cell lymphoma can come back as a slower-growing type of lymphoma to see what signs and treatments might help patients better.

  Recruiting Azienda USL Reggio Emilia - IRCCS · Reggio Emilia · NCT06822829

• HPV vaccination after allogeneic stem cell transplant

  This trial will test whether giving the 9‑valent HPV vaccine early or later after an allogeneic stem cell transplant produces a protective antibody response in adults up to age 45 who had a transplant.

  Recruiting at 3 sites Phase 2 Vastra Gotaland Region · Lund, Region Skåne and 4 other locations · NCT06793410

• Treatment for Diffuse Large B-cell Lymphoma using Glofitamab

  This study is testing a new combination of treatments for people with diffuse large B-cell lymphoma to see if it works better and has fewer side effects than current options.

  Recruiting at 8 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 7 other locations · NCT06765317

• Combining orelabrutinib with R-CHOP for treating CD5-positive DLBCL

  This study is testing if adding a new drug called orelabrutinib to the standard R-CHOP treatment can help people with untreated CD5-positive diffuse large B-cell lymphoma live longer without their cancer coming back.

  Recruiting at 11 sites Phase 2 Sun Yat-sen University · Guangzhou, China and 10 other locations · NCT06647940

• Mosunetuzumab and Polatuzumab Vedotin with split-dose CHP in older adults with DLBCL

  This phase 2 study tests whether adding Mosunetuzumab subcutaneous and Polatuzumab Vedotin to a split-dose CHP chemotherapy regimen helps elderly, newly diagnosed DLBCL patients who are frail or unfit.

  Recruiting Phase 2 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT06594939

• Treatment for relapsed B cell lymphoma using CAR-NK and CAR-T cells

  This study is testing a new treatment for people with relapsed B cell lymphoma that uses two types of immune cells, CAR-NK and CAR-T, to see if it helps them feel better.

  Recruiting Phase 1 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT06464861

• Odronextamab with chemo vs rituximab with chemo in untreated DLBCL

  A new treatment approach using odronextamab plus chemotherapy is being tested to see if it works better and is as safe as rituximab plus chemotherapy for adults with newly diagnosed diffuse large B-cell lymphoma.

  Recruiting at 182 sites Phase 3 Regeneron Pharmaceuticals · Scottsdale, Arizona and 194 other locations · NCT06091865

• Using Glofitamab to Improve Treatment for Untreated Diffuse Large B Cell Lymphoma

  This study is testing if adding a new drug called glofitamab to standard treatment can help people with untreated diffuse large B cell lymphoma have better outcomes.

  Recruiting at 2 sites Phase 2 University Health Network, Toronto · Toronto, Ontario and 2 other locations · NCT06050694

• Registry platform for patients with blood cancers in Germany

  This study is setting up a national registry to collect information from patients with blood cancers in Germany to see how well different treatments work and what patients need.

  Recruiting iOMEDICO AG · Freiburg im Breisgau · NCT06043011

• Healthy Lifestyle Plan for Lymphoma Survivors

  This study is testing whether a special health plan that includes lifestyle changes and nutrition advice can help lymphoma survivors feel better after they've been in remission for a while.

  Recruiting at 34 sites Fondazione Italiana Linfomi - ETS · Ancona, Ancona and 39 other locations · NCT05934084

• Evaluation of CAR-T cell therapy in certain blood cancers

  This study is testing how well CAR-T cell therapy works and lasts in patients with certain types of blood cancers, while also looking for signs that could predict how they respond to treatment and any side effects they might have.

  Recruiting Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · Brescia · NCT05366569

• Evaluating NX-5948 for advanced B-cell cancers

  This study is testing a new drug called NX-5948 to see if it can safely help adults with tough-to-treat B-cell cancers feel better.

  Recruiting at 53 sites Phase 1 Nurix Therapeutics, Inc. · Duarte, California and 61 other locations · NCT05131022

• Evaluating NX-1607 for advanced cancers

  This study is testing a new treatment called NX-1607 to see if it can help people with advanced cancers who have run out of other options.

  Recruiting at 15 sites Phase 1 Nurix Therapeutics, Inc. · Duarte, California and 16 other locations · NCT05107674

• Efficacy and safety of CRC01 for adult patients with large B-cell lymphoma

  This study is testing a new CAR-T therapy called CRC01, combined with other medications, to see if it can help adults with hard-to-treat large B-cell lymphoma feel better.

  Recruiting at 2 sites Phase 1/2 Curocell Inc. · Seoul and 1 other locations · NCT04836507

• Evaluating NX-2127 for adults with advanced B-cell cancers

  This study is testing a new treatment called NX-2127 to see if it can help adults with advanced B-cell cancers feel better and fight their disease.

  Recruiting at 7 sites Phase 1 Nurix Therapeutics, Inc. · Duarte, California and 15 other locations · NCT04830137

• Evaluating oral abexinostat for patients with relapsed or refractory DLBCL

  This study is testing if an oral medication called abexinostat can help people with relapsed or hard-to-treat diffuse large B-cell lymphoma feel better after trying other treatments.

  Recruiting at 23 sites Phase 2 Xynomic Pharmaceuticals, Inc. · Beijing and 22 other locations · NCT03936153

Related topics

Quick answers

How many Diffuse Large B Cell Lymphoma (DLBCL) clinical trials are recruiting right now?

41, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 31 countries. The most sites are in China (19 trials), United States (10 trials), Italy (5 trials), United Kingdom (4 trials), South Korea (4 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 17, Phase 1: 7, Phase 1/2: 6, Phase 3: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →